ReviewFrontiers in immunology2025
Activated PI3K-δ syndrome presenting with cervical lymphadenopathy in a pediatric patient: a case report and review of the literature.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolution of Inborn Errors of Immunity in China: Discoveries and Treatment Paradigms.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Activated phosphoinositide 3-kinase delta syndrome (APDS) is a primary immunodeficiency caused by gain-of-function mutations in the PIK3CD gene, leading to dysregulated immune responses. Clinical manifestations include recurrent infections, lymphoproliferation, and increased risk of malignancies. Due to its rarity and variable presentation, APDS is often misdiagnosed or diagnosed late. Case presentation: We report a case of a 12-year-old girl presenting with persistent cervical lymphadenopathy. Imaging studies revealed extensive lymph node involvement and splenomegaly. PET-CT raised suspicion for lymphoma. Histopathology of the excised lymph node demonstrated Epstein-Barr virus (EBV) latent infection Type III, while whole exome sequencing identified a pathogenic PIK3CD c.3061G>A (p.Glu1021Lys) heterozygous variant. This confirmed the diagnosis of APDS. Targeted therapy with sirolimus was initiated, leading to significant regression of lymphadenopathy and splenomegaly. The patient maintained good clinical status during follow-up. Conclusion: This case highlights the importance of genetic testing in pediatric patients with lymphoproliferative disease and unusual infection patterns. Early diagnosis of APDS enables personalized, targeted treatment and avoids overtreatment with cytotoxic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.